Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0904558 on December 23, 2004

Published online before print December 23, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0904558v1
77/3/281    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarz, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarz, H.
(Journal of Leukocyte Biology. 2005;77:281-286.)
© 2005 by Society for Leukocyte Biology

Biological activities of reverse signal transduction through CD137 ligand

Herbert Schwarz1

Department of Physiology, National University of Singapore

1 Correspondence: Department of Physiology, National University of Singapore, 2 Medical Drive, MD 9, Singapore 117597. E-mail: phssh{at}nus.edu.sg

CD137 is a member of the tumor necrosis factor receptor family and a potent regulator of T cell activities. Agonists of CD137 have been used widely and successfully to treat cancer in animal models, and recently, it has become evident that CD137 agonists can also be used to treat autoimmune disease. An aspect of the CD137 receptor/ligand system, which has been comparatively little-explored, is its ability of reverse signaling. Just as is CD137, the CD137 ligand is also expressed as a cell membrane protein, and it too can transduce signals into the cells on which it is expressed. This bidirectional signaling capacity allows the CD137 receptor/ligand system to mediate extensive cross-talk between immune cells and between immune and nonimmune cells. This review summarizes the known activities of the CD137 ligand on the different leukocyte subsets and on cancer cells and discusses their influence on the course of immune responses.

Key Words: TNF superfamily family • reverse signaling • bidirectional signal transduction




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Sun and P. J. Fink
A New Class of Reverse Signaling Costimulators Belongs to the TNF Family
J. Immunol., October 1, 2007; 179(7): 4307 - 4312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Yang, S. Yang, Z. Ye, J. Jaffar, Y. Zhou, E. Cutter, A. Lieber, I. Hellstrom, and K. E. Hellstrom
Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment
Cancer Res., March 1, 2007; 67(5): 2339 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. Drenkard, F. M. Becke, J. Langstein, T. Spruss, L. A. Kunz-Schughart, T. E. Tan, Y. C. Lim, and H. Schwarz
CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity
FASEB J, February 1, 2007; 21(2): 456 - 463.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-W. Lee, A. T. Vella, B. S. Kwon, and M. Croft
Enhanced CD4 T Cell Responsiveness in the Absence of 4-1BB
J. Immunol., June 1, 2005; 174(11): 6803 - 6808.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Leukocyte Biology.